REG - Indivior PLC - Notice of Results
RNS Number : 2327EIndivior PLC17 October 2018Indivior to Announce 2018 Third Quarter and Year-to-Date Results on November 1st
Slough, UK, and Richmond, VA, 17 October 2018 - Indivior PLC (LON: INDV) today announced that it will release its 2018 third quarter and year-to-date results on Thursday, November 1st at 11:00 a.m. London time (7:00 a.m. U.S. Eastern). The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the company's website at www.indivior.com.
Key members of Indivior's leadership team led by Shaun Thaxter, Chief Executive Officer, will host a conference call to discuss the results and address questions from qualified analysts and investors at 12 noon London time (8:00 a.m. U.S. Eastern) on November 1st.
Access the Live Webcast for the Results Call on Thursday, November 1st
The webcast event will be available on the "Investors" section of the company's website at www.indivior.com. The webcast link is https://edge.media-server.com/m6/p/bqwwyn7f. Participants also may access the results presentation telephonically: US participants +1-929-477-0324; international participants +44(0)330-336-9105. Please reference confirmation number 4593067. A replay of the presentation will be available at www.indivior.com.
About Indivior
Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy and health policy while providing education on evidence-based treatment models that have revolutionized modern addiction treatment. The name is the fusion of the words individual and endeavor, and the tagline "Focus on you" makes the Company's commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder and schizophrenia. Headquartered in the United States in Richmond, VA, Indivior employs more than 1,000 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more.
Contact:
Jason Thompson
Vice President, Investor Relations
Tel: 804-379-1033 or jason.thompson@indivior.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDNOREADEKFDAPFFF
Recent news on Indivior
See all newsREG - Indivior PLC - Transaction in Own Shares
AnnouncementREG - Indivior PLC - Notice of Results
AnnouncementREG - Indivior PLC - Preliminary Q3 Results & Updated FY 2024 Guidance
AnnouncementREG - Indivior PLC - Transaction in Own Shares
AnnouncementREG - Indivior PLC - Chair Succession Plan
Announcement